Note:  We are no longer accepting Zimmer NexGen Knee cases. 

Knee replacement failure, revision surgery, loosening of the implant after replacement and knee pain or knee complications are some of the reports that are driving concerns regarding Zimmer NexGen CR and NexGen CR-Flex knee replacement components. The components in question were used in Zimmer NexGen Tibial Trays, NexGen MIS Tibial components and MIS Modular Tibial Plates.

knee replacements

Lawsuits filed over Zimmer NexGen knee replacements

About two dozen lawsuits have been filed around the country alleging that Zimmer NexGen knee replacements are defective and the company failed to warn that they have a high rate of failure requiring additional revision surgery.

Plaintiffs’ lawyers filed a petition to consolidate the cases before a multidistrict litigation panel.

Randi Kassan, a plaintiffs’ attorney with Sanders Phillips Grossman, said her firm first noticed an uptick in internet complaints around the knee replacements and has been looking into claims for over a year and a half.

 

Zimmer® NexGen®

Zimmer Nexgen Knee Implant Products Liability litigation, case number 2272, in the U.S. District Court for the Northern District of Illinois.

Plaintiffs in the multidistrict litigation claim the engineering changes that Zimmer made to NexGen CR-Flex knee replacement to allow a greater degree of flexibility in its NexGen components caused greater stress on the knee implants. The lawsuits argue that the high-flex knee implants often force patients to undergo revision surgery and question whether the products actually increase flexion.

Knee Implant

Zimmer® Knee Implant Actions Merged Into MDL

Posted on August 9, 2011 – Bible Shrestha, Law360.

The U.S. Judicial Panel on Multidistrict Litigation created a new MDL in Illinois on Monday, centralizing 28 lawsuits that claim Zimmer Inc.’s NexGen high-flex knee implant components prematurely loosen, causing patients significant pain and loss of movement.

The litigation, brought in 13 districts and centralized in the Northern District of Illinois, concern Zimmer’s Cruciate Retaining, Legacy Posterior Stabilized and Gender Solutions femoral components as well as its MIS Tibial component, all of which are used in knee replacement surgery. After plaintiff Fred Stone moved to centralize the lawsuits, the JPML learned of 45 additional actions that could potentially join the MDL.

Zimmer had vigorously opposed centralization, arguing that there would be no significant overlap in discovery because the actions before the panel involve eight products, six design teams, six different sets of design history documents and eight different regulatory applications.

The judicial panel disagreed, persuaded by the plaintiff’s arguments that Zimmer’s submissions to the U.S. Food and Drug Administration reflected major similarities among the products and that surgical techniques brochures for the LPS-Flex and CR-Flex components used largely identical language to describe the products’ designs.

“Centralization … will eliminate duplicative discovery, prevent inconsistent pretrial rulings … and conserve the resources of the parties, their counsel and the judiciary,” the JPML’s order said.

Jim Ronca, an Anapol Schwartz Weiss Cohan Feldman & Smalley PC attorney representing Stone, said Tuesday that the Nexgen components at issue were all part of one product line and contained the same defect. Ronca said he failed to understand why Zimmer argued against centralization.

“I think their real motive was that they wanted to divide and conquer the plaintiffs,” Ronca said. “We anticipate there will be hundreds of cases if not over a thousand … It could only be efficiently run in front of one judge.”

Jay Yeager, a Baker & Daniels LLP attorney representing Zimmer, said that he respected the panel’s decision. “We look forward to defending the merits of these very successful and widely used products,” Yeager said.

According to Ronca, Zimmer’s NexGen high-flex components theoretically allow patients to bend their knees by 155 degrees, while standard NexGen components provide for up to 125 degrees of bending, or flexion.

Plaintiffs in the multidistrict litigation claim the engineering changes that Zimmer made to allow a greater degree of flexibility in its NexGen components caused greater stress on the knee implants. The lawsuits argue that the high-flex knee implants often force patients to undergo revision surgery and question whether the products actually increase flexion.

Despite Zimmer’s request to locate the MDL in Indiana, the JPML decided to consolidate the cases in Illinois federal court.

“Ten of the 28 constituent actions are pending in that district, and the district is relatively close to Zimmer’s Indiana headquarters,” the JPML said.

Zimmer is represented by Jay Yeager Jr. of Baker & Daniels LLP.

 

Surgeon vs. Knee Maker

Surgeon vs. Knee Maker: Who’s Rejecting Who?

Posted on June 19, 2010 – Barry Meier, New York Times.

It was a long, fruitful medical marriage that is fast becoming an angry public divorce, one that offers a rare look at a clash between a top-shelf consultant and his corporate patron over patient safety.

For years, Dr. Richard A. Berger designed surgical tools and artificial joints for Zimmer Holdings, trained hundreds of doctors to use its products and talked it up wherever he went. In return, Zimmer, an orthopedic implant maker, helped enrich Dr. Berger, portraying him as a master surgeon and paying him more than $8 million over a decade.

Those days are gone. Dr. Berger started complaining to Zimmer a while back that one of its artificial-knee models was failing prematurely, and he went public recently with a study that he says proves it. Zimmer told him that the problem was not the artificial knee, but his technique, and pointed to data overseas indicating that the knee was safe.

Last year, Zimmer did not give Dr. Berger a new contract. The company says it routinely rotates consultants.

“I trained hundreds of doctors for them and made them tens of millions,” Dr. Berger said in interview here, in which he also lambasted Zimmer executives as dissembling, out-of-touch bureaucrats. “So was this just a coincidence? Maybe it was. Maybe it wasn’t.”

Zimmer executives declined to be interviewed. The company said in a statement that it had thoroughly investigated Dr. Berger’s complaints in 2006 and that he had disagreed with its findings.

Amid the booming use of artificial joints in the United States, the breakup between Dr. Berger and Zimmer highlights what experts say is a troubling situation for patients and doctors: when disputes arise about orthopedic implant safety, there are no independent referees or sources of information because no one tracks the performance of the devices.

“There is no way of knowing who is right because we don’t have the data,” said Dr. Kevin J. Bozic, a professor of orthopedic surgery at the University of California, San Francisco.

While producers of implanted heart devices have a voluntary system in which outside panels investigate problems, American makers of orthopedic devices do not. Many of the artificial joints that surgeons like Dr. Berger use, including the Zimmer knee at issue, are cleared under law by the Food and Drug Administration for sale without testing in patients. In addition, no one in the country tracks the long-term performance of artificial hips and knees, a $6.7 billion annual business that surged as baby boomers reached middle age.

Those with the most to lose are the hundreds of thousands of people who receive an orthopedic device each year.

One patient, Lisé Markham, said she underwent surgery recently to replace a flawed hip just two years after getting it. She said the experience awakened her to how little patients can find out about an implant’s track record.

“My doctor knew everything about me, every personal detail, but what did I know on the other side?” said Ms. Markham, who lives in San Diego.

Two years ago, another top Zimmer consultant, Dr. Lawrence Dorr of Los Angeles, alerted surgeons that a company hip model was failing after a few years. Zimmer shot back, saying the problem was Dr. Dorr’s technique, not the device. Along with briefly halting sales, it also provided the F.D.A. with data from 12 surgical centers showing that the hip was working well. Based on that, the agency decided to close its investigation, said an F.D.A. spokeswoman, Mary Long.

But in interviews, two doctors who provided Zimmer with supportive data in 2008 said the hip started failing soon afterward in their patients, too. One, Dr. Richard Illgen of the University of Wisconsin, said he now realizes that Dr. Dorr’s technique was not the issue, but that Dr. Dorr had just started using the Zimmer hip before other surgeons. Zimmer still defends the product, which is known as the Durom hip.

These days, companies like Zimmer have fewer consultants, part of the fallout from settlements in 2007 by several companies, including Zimmer, of Justice Department charges that consultant payments were used to disguise kickbacks to surgeons. However, relationships with Dr. Berger and Dr. Dorr were not called into question.

About a decade ago, when the relationship between Dr. Berger and Zimmer began, it was filled with promise. The surgeon, a tall, balding man with a boyish manner, was finishing his fellowship at the Rush University Medical Center in Chicago at the time, one of the country’s top centers for joint replacement. The center has had long ties to Zimmer, whose headquarters is about two hours away, in Warsaw, Ind., and the young surgeon quickly came to the company’s attention.

“Rich has a very clever set of hands, and because of that he is enabled with the ability to innovate surgical techniques,” said Roy Crowninshield, who was Zimmer’s chief scientific officer.

Dr. Berger’s skills matched Zimmer’s marketing strategy. To distinguish itself from competitors, the device maker had started promoting minimally invasive surgery, a technique that uses smaller incisions than traditional surgery. Zimmer trained doctors in the procedure, using its device.

Soon, Dr. Berger, who was then pioneering a type of small-incision surgery that allowed patients to leave the hospital on the day of surgery, became a linchpin of Zimmer’s efforts. In 2002, he was prominently featured in a press release about Zimmer’s plans to build a training facility for minimally invasive surgery.

“We are clearly excited about Dr. Berger’s data,” J. Raymond Elliott, the company’s chairman and chief executive at the time, stated in the release.

Over the next few years, the physician estimates, he helped train hundreds of surgeons on Zimmer’s behalf. His star also rose: he and his technique were featured on “World News Tonight” on ABC, and he was soon performing about 1,000 hip and knee replacements annually, nearly all with Zimmer devices.

But Dr. Berger, who is 47, with energy and self-confidence to spare, also became a lightning rod. Other doctors questioned whether his technique of using such a small incision could be broadly adopted, and interest in his approach fell. The concern was that such a tiny opening left doctors with little room for error.

Dr. Berger brushes off complaints, saying that many surgeons do not have the skill or the patience to learn his technique. “There are lots of reasons that people don’t want to do something new,” he said.

As he tells it, his relationship with Zimmer frayed over a version of a widely used Zimmer knee, known as the NexGen. The model at issue, called the NexGen CR-Flex, is designed to provide a greater range of motion than the standard NexGen.

Most surgeons implant an artificial knee using a cement-like adhesive to bond the thigh bone to the portion of the device that bends. But some specialists, like Dr. Berger, try to avoid adhesives because the cement can break down and cause device failure. So Zimmer also sells an uncemented version of the CR-Flex that relies instead on the bone naturally fusing with the implant.

Dr. Berger says that he gave the device, which is supposed to last about 15 years, to about 125 patients in 2005, the first full year he used it. But by early 2006, some X-rays showed lines where the implant met the thigh bone, an indication that the device was loose and had not fused completely. Patients could walk, but they were reporting pain, apparently a result of the loose joint.

He says he soon brought the problem to the attention of Zimmer officials, including the company’s new top scientist, Cheryl R. Blanchard. Zimmer executives pointed to the success of the NexGen, but the company did not have separate test data on the uncemented flexible model because the F.D.A. had not required the company to study it in patients before selling it.

Later, as more patients complained about the device and Dr. Berger had to replace some of them, he spoke to Ms. Blanchard again, he said. This time, he said, she and other Zimmer officials suggested that his technique was the problem because no other surgeon had complained.

“Suddenly, I went from someone who was their master teacher to someone who didn’t know what he was doing,” he said.

By 2007, Dr. Berger, although still a Zimmer consultant, had stopped using the device and had learned, he said, that several other surgeons had also experienced problems with it. But unlike Dr. Dorr, the physician who sent out the alert about Zimmer, Dr. Berger said he initially had hoped to avoid a public showdown with the company. So he followed a more traditional route by performing a study with another Rush surgeon, Dr. Craig J. Della Valle, who was also having to replace the Zimmer knee.

Dr. Berger and Dr. Della Valle first presented their study at a medical meeting last fall and again this year at a national meeting of the American Association of Orthopedic Surgeons. They found that the uncemented Zimmer knee failed early in about 9 percent of some 100 patients studied. Also, the knee exhibited signs of looseness in about half of all patients and has since been replaced in some of them, Dr. Berger said.

But Zimmer was unswayed. In a filing with the Securities and Exchange Commission, Zimmer made note of the study but also pointed to the knee’s very positive results in a large database of orthopedic patients in Australia. Officials there confirmed the low failure rate. The company also said that the cement-free CR Flex accounted for only a small fraction – about 2 percent – of its overall knee sales.

Zimmer said that collaboration with surgeons like Dr. Berger was critical to the success of its products. “To date, Dr. Berger remains a valued customer of Zimmer,” the company stated.

That may also change soon. Dr. Berger said he was talking with another device maker about consulting and is trying out other products.

As for Zimmer, he said, “I have lost confidence.”

 

About Us

About Sanders Phillips Grossman

Sanders Phillips Grossman has been holding pharmaceutical companies responsible for injuring individuals by their defective drugs and devices for over 30 years. Defective drugs are pharmaceuticals with side effects that potentially harm, injure, or kill the patient to the point that they outweigh the drug’s intended benefits. Defective devices, such as faulty prosthetics, implants, pacemakers or surgical instruments can harm patients when the product is defective in the manufacturing process, design or marketing strategy.

Pharmaceutical companies are some of the largest, wealthiest, and most influential corporate entities in the world. Sanders Phillips Grossman and its predecessors have recovered over one billion dollars for injured consumers. Our firm’s history in dealing with drug and medical device injury claims has allowed us to take leadership roles in many of the national defective drug and device litigations.

Nationally recognized as a leading plaintiff’s law firm, we handle cases in all 50 states and Puerto Rico.

Read more about our attorneys here.

 

Contact Us

How can we help you?
Fill out the form below and we’ll be in touch shortly.